Clinical implications of the serum CA19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancer

Hidenori Takahashi, Daisaku Yamada, Kei Asukai, Hiroshi Wada, Shinichiro Hasegawa, Hisashi Hara, Naoki Shinno, Hajime Ushigome, Naotsugu Haraguchi, Keijiro Sugimura, Kazuyoshi Yamamoto, Junichi Nishimura, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Masayuki Ohue, Masahiko Yano, Masato Sakon, Osamu Ishikawa